Macrophage Programming for Immunotherapy

Tech ID: 28866 / UC Case 2017-142-0

Background

Immunotherapy is one of the most important areas in modern medicine. Using antibodies, proteins, and cells, physicians are now able to target a range of conditions with specificity. UC San Diego researchers have recently developed a new process for engineering macrophages to possess a broad range of sensing and programed actions for directed therapeutics.

Technology Description

UC San Diego researchers have developed methods and processes for engineering macrophages to carry both response elements and effector modules that can provide directed immunotherapy. By modulating the cellular response profile, macrophages can now target cells that would otherwise evade detection and clearance. By relying on the natural phagocytic process, the therapeutic potential of this technology is enhanced and the off-target risks may be minimized.

Applications

Potential use in directed therapeutics for immunotherapy.

Advantages

By relying on the natural phagocytic process, the therapeutic potential of this technology is enhanced and the off-target risks may be minimized.

Intellectual Property Info

A provisional patent has been submitted.

Patent Status

Country Type Number Dated Case
United States Of America Published Application 0140834-A1 05/07/2020 2017-142
Patent Cooperation Treaty Published Application 2019014419 01/17/2019 2017-142
 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Keywords

Cell therapy, Immunotherapy, macrophage, precision medicine, natural phagocytosis

Categorized As